Posted by Admin
Post Date : Friday November 2 2007

ES is a 64-year old Caucasian male who was diagnosed with stage 4 carcinoma of the esophagus in April 2007 confirmed via esophagogastroduodenoscopy. The biopsy showed poorly differentiated adenocarcinoma. Initial urinalysis was clear. His blood chemistry studies performed on 4/20/07 were essentially normal with a slight elevation of glucose 123 mg/dl. The alkaline phosphatase was slightly elevated at 149 (normal 40-120 U/L). Iron saturation was slightly low and liver function tests were normal. The CEA was elevated at 10.5 (normal 0-5.0 ng/ml). His CT scan revealed the cancer had metastasized to his liver. A PET scan performed on 4/25/07 showed evidence of a hypermetabolic esophageal mass consistent with a history of esophageal cancer. Multiple liver metastasis were noted. A left supraclavicular node and gastrohepatic node were likely involved. There was also some uptake in the region of the right scapula with uncertain signficance. At least 10 metastatic lesions were seen and involved in both lobes of the liver. The patient wanted to pursue and integrative approach to his cancer treatment and was seen at the medical center on 5/2/07 for an evaluation. He was complaining of dysphagia and odynophagia (painful swallowing). He had already started chemotherapy treatment with his oncologist. ES elected the integrative approach to the management of his cancer with Poly-MVA and supportive dietary supplements as well as a low glycemic index diet. He received 40 cc of Poly-MVA (filtered) via intravenous administration in 250 cc normal saline. He received the treatment three times each week for 8 weeks for a total of 24 treatments from 5/2/07 through 7/6/07. On the non-IV days, he took the 8 tsp/day of Poly-MVA orally. A follow up PET scan performed on 6/25/07 showed dramatic improvement. There was no evidence of involvement of the distal esophagus, liver or supraclavicular node. The PET report stated, “Currently there is no PET evidence for malignancy.” ES remains on oral Poly-MVA and supportive supplements including CoQ10, omega-3 fatty acids, vitamin D and low dose naltrexone. He will continue the Poly-MVA orally at 8 tsp/day for several months pending follow up. ES recently elected to take intravenous vitamin C as an adjunct as well. Clinically this patient had a dramatic complete resolution of his cancer as evidenced by a CT report. He will receive long term follow up and will resume the Poly-MVA intravenous protocol if there is a recurrence. The chemotherapy he was given by the oncologist was for palliative care and to slow the progression.

Case study written by Dr. Paul Rothwell and Dr. Shari Lieberman as a part of the Poly-MVA Best Case Series.